JP2005506277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506277A5 JP2005506277A5 JP2002554126A JP2002554126A JP2005506277A5 JP 2005506277 A5 JP2005506277 A5 JP 2005506277A5 JP 2002554126 A JP2002554126 A JP 2002554126A JP 2002554126 A JP2002554126 A JP 2002554126A JP 2005506277 A5 JP2005506277 A5 JP 2005506277A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- agent
- type
- heavy chain
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 35
- 230000008685 targeting Effects 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 6
- 229940094657 botulinum toxin type a Drugs 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 108030001720 Bontoxilysin Proteins 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 229940053031 botulinum toxin Drugs 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 210000000805 cytoplasm Anatomy 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims 3
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000008300 Mutant Proteins Human genes 0.000 claims 2
- 108010021466 Mutant Proteins Proteins 0.000 claims 2
- 108010055044 Tetanus Toxin Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940118376 tetanus toxin Drugs 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 230000005945 translocation Effects 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 108010084592 Saporins Proteins 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000001617 migratory effect Effects 0.000 claims 1
- 230000003957 neurotransmitter release Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000003705 ribosome Anatomy 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/751,053 US6787517B1 (en) | 2000-12-29 | 2000-12-29 | Agent and methods for treating pain |
| PCT/US2001/048651 WO2002053177A2 (en) | 2000-12-29 | 2001-12-14 | Agents and methods for treating pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506277A JP2005506277A (ja) | 2005-03-03 |
| JP2005506277A5 true JP2005506277A5 (enExample) | 2005-12-22 |
Family
ID=25020269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002554126A Pending JP2005506277A (ja) | 2000-12-29 | 2001-12-14 | 疼痛治療のための薬剤および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6787517B1 (enExample) |
| EP (1) | EP1363674A2 (enExample) |
| JP (1) | JP2005506277A (enExample) |
| AU (1) | AU2002229075B2 (enExample) |
| CA (1) | CA2433332A1 (enExample) |
| WO (1) | WO2002053177A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
| DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
| US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US7335803B2 (en) * | 2001-10-19 | 2008-02-26 | Allergan, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| US20070048335A1 (en) * | 2000-12-29 | 2007-03-01 | Allergan, Inc. | Methods for treating pain and hyperhidrosis |
| US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| US20060153876A1 (en) * | 2003-02-24 | 2006-07-13 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease |
| WO2004078200A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Selection of patients with increased responsiveness to botulinum toxin |
| US20050059664A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
| US20060293359A1 (en) * | 2003-06-25 | 2006-12-28 | Allergan, Inc. | Methods and compositions for the treatment of diabetes |
| US20050191321A1 (en) | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
| US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| CA2588758C (en) * | 2004-11-22 | 2017-01-03 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| US7910116B2 (en) * | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
| AU2006339490B2 (en) * | 2005-09-19 | 2011-12-08 | Allergan, Inc. | Clostridial toxin activatable clostridial toxins |
| US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
| US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
| ES2526398T3 (es) | 2006-12-22 | 2015-01-12 | Allergan, Inc. | Composiciones inhibidoras de la recaptación de serotonina-norepinefrina para tratar el dolor crónico |
| US20080153825A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders |
| US20120083508A1 (en) | 2006-12-22 | 2012-04-05 | Allergan, Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| US20080153874A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| US20080153927A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders |
| US20080153881A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders |
| US20100216857A1 (en) * | 2007-10-18 | 2010-08-26 | Luhrs Lauren M B | Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione |
| WO2009052075A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating motor disorders with alpha-2b adrenergic receptor agonists |
| WO2009052073A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
| US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
| US8617571B2 (en) * | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
| US20100086567A1 (en) * | 2008-10-01 | 2010-04-08 | Clemens Ii Mark Warren | Botulinum toxin therapy for prevention of anastamotic thrombosis in free tissue transfer |
| US20100124559A1 (en) * | 2008-11-20 | 2010-05-20 | Allergan, Inc. | Early Treatment and Prevention of Increased Muscle Tonicity |
| ES2669020T3 (es) | 2008-12-31 | 2018-05-23 | Revance Therapeutics, Inc. | Formulaciones inyectables de toxina botulínica |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| JP6043627B2 (ja) | 2009-06-25 | 2016-12-14 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | アルブミン非含有ボツリヌス毒素製剤 |
| WO2011017564A2 (en) * | 2009-08-06 | 2011-02-10 | California Institute Of Technology | Identification and use of compounds for treating persistent pain |
| EP2470181A1 (en) | 2009-08-26 | 2012-07-04 | Allergan, Inc. | Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists |
| EP2605771B1 (en) | 2010-08-16 | 2018-04-04 | Allergan, Inc. | Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| US9315549B2 (en) | 2013-01-28 | 2016-04-19 | New York University | Treatment methods using atoxic neurotoxin derivatives |
| US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
| WO2016094555A1 (en) | 2014-12-09 | 2016-06-16 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939145A (en) * | 1973-03-01 | 1976-02-17 | Strategic Medical Research Corporation | Novel ethereally monosubstituted monosaccharides |
| US5053337A (en) * | 1989-10-30 | 1991-10-01 | Neurogenetic Corporation | DNA encoding an α2B -adrenergic receptor |
| US5447947A (en) * | 1990-02-26 | 1995-09-05 | Arc 1 | Compositions and methods of treatment of sympathetically maintained pain |
| US5223408A (en) | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
| ES2138740T3 (es) | 1994-05-31 | 2000-01-16 | Allergan Inc | Modificacion de toxinas de clostridium utilizadas como proteinas de transporte. |
| EP0770068B1 (en) * | 1994-07-11 | 2001-11-28 | Allergan Sales, Inc. | Conformationally rigid bicyclic and adamantane derivatives useful as alpha 2-adrenergic blocking agents |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US6139819A (en) * | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6545182B2 (en) | 2000-04-13 | 2003-04-08 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US6313172B1 (en) * | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
-
2000
- 2000-12-29 US US09/751,053 patent/US6787517B1/en not_active Expired - Fee Related
-
2001
- 2001-12-14 WO PCT/US2001/048651 patent/WO2002053177A2/en not_active Ceased
- 2001-12-14 CA CA002433332A patent/CA2433332A1/en not_active Abandoned
- 2001-12-14 EP EP01990212A patent/EP1363674A2/en not_active Withdrawn
- 2001-12-14 AU AU2002229075A patent/AU2002229075B2/en not_active Ceased
- 2001-12-14 JP JP2002554126A patent/JP2005506277A/ja active Pending
-
2004
- 2004-03-01 US US10/791,434 patent/US20040146532A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105073133B (zh) | 抗gdf15抗体 | |
| Abarbri et al. | Preparation of new polyfunctional magnesiated heterocycles using a chlorine−, bromine−, or iodine− magnesium exchange | |
| RU2345067C2 (ru) | Ингибиторы дпп-iv | |
| JP2013506628A (ja) | 延長された半減期を有する薬物融合物及びコンジュゲート | |
| JP5009376B2 (ja) | グルカゴン様タンパク質１受容体（ｇｌｐ−１ｒ）アゴニスト化合物 | |
| US20200392108A1 (en) | Antibody-drug conjugates and related compounds, compositions and methods | |
| NO20061394L (no) | Fullstendig humane antistoffer mot human 4-1BB (CD137) | |
| CN1152870A (zh) | 杂环化合物作为多巴胺d3配位体的用途 | |
| ATE513563T1 (de) | Therapeutische und toleranz-induzierende antikörper | |
| CN1768861A (zh) | 用于治疗或预防尼古丁成瘾的半抗原－载体偶联物 | |
| JP2014502955A5 (enExample) | ||
| KR20090127902A (ko) | 벤즈이미다졸 유도체 및 이의 사용방법 | |
| TW200815422A (en) | Heteroaryl derivatives as cytokine inhibitors | |
| CN102203074A (zh) | 芳基gpr119激动剂及其用途 | |
| ATE486090T1 (de) | Erfindung betreffend glp-1 und exendin | |
| JP2008513498A5 (enExample) | ||
| JP2011515341A5 (enExample) | ||
| EA024702B1 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
| JP6855496B2 (ja) | 抗ｃｄ２２抗体−メイタンシンコンジュゲートおよびその使用方法 | |
| WO2002053177A3 (en) | Agents and methods for treating pain | |
| Duryee et al. | Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines | |
| CA2767112A1 (en) | Etomidate analogues that do not inhibit adrenocortical steroid synthesis | |
| KR20130086623A (ko) | 항-당뇨병 화합물 | |
| NL8403318A (nl) | Nieuwe 7-carboxymethoxy-furo-(3,4-c)-pyridinederivaten, hun bereiding en therapeutische preparaten die ze bevatten. | |
| TW200524903A (en) | Quinazoline derivatives |